|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM, Pisani P and Ferlay J: Global
cancer statistics. CA Cancer J Clin. 49:33–64. 1999. View Article : Google Scholar
|
|
3
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
4
|
Blot WJ, McLaughlin JK, Winn DM, Austin
DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB,
Stemhagen A and Fraumeni JF Jr: Smoking and drinking in relation to
oral and pharyngeal cancer. Cancer Res. 48:3282–3287.
1988.PubMed/NCBI
|
|
5
|
Franceschi S, Talamini R, Barra S, Barón
AE, Negri E, Bidoli E, Serraino D and La Vecchia C: Smoking and
drinking in relation to cancers of the oral cavity, pharynx,
larynx, and esophagus in northern Italy. Cancer Res. 50:6502–6507.
1990.PubMed/NCBI
|
|
6
|
Zheng TZ, Boyle P, Hu HF, Duan J, Jiang
PJ, Ma DQ, Shui LP, Niu SR and MacMahon B: Tobacco smoking, alcohol
consumption, and risk of oral cancer: a case-control study in
Beijing, People’s Republic of China. Cancer Causes Control.
1:173–179. 1990.
|
|
7
|
Choi S and Myers JN: Molecular
pathogenesis of oral squamous cell carcinoma: implications for
therapy. J Dent Res. 87:14–32. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bensaad K and Vousden KH: p53: new roles
in metabolism. Trends Cell Biol. 17:286–291. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lozano G and Zambetti GP: What have animal
models taught us about the p53 pathway? J Pathol. 205:206–220.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Agarwal A, Rani M, Saha GK, Valarmathi TM,
Bahadur S, Mohanti BK and Das SN: Disregulated expression of the
Th2 cytokine gene in patients with intraoral squamous cell
carcinoma. Immunol Invest. 32:17–30. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stransky N, Egloff AM, Tward AD, Kostic
AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C,
McKenna A, et al: The mutational landscape of head and neck
squamous cell carcinoma. Science. 333:1157–1160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grandis JR and Tweardy DJ: Elevated levels
of transforming growth factor alpha and epidermal growth factor
receptor messenger RNA are early markers of carcinogenesis in head
and neck cancer. Cancer Res. 53:3579–3584. 1993.
|
|
13
|
Rubin Grandis J, Melhem MF, Gooding WE,
Day R, Holst VA, Wagener MM, Drenning SD and Tweardy DJ: Levels of
TGF-alpha and EGFR protein in head and neck squamous cell carcinoma
and patient survival. J Natl Cancer Inst. 90:824–832. 1998.
|
|
14
|
Grandis JR and Tweardy DJ: TGF-alpha and
EGFR in head and neck cancer. J Cell Biochem Suppl. 17F:188–191.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Herbst RS, Giaccone G, Schiller JH, Natale
RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves
JA, et al: Gefitinib in combination with paclitaxel and carboplatin
in advanced non-small-cell lung cancer: a phase III trial - INTACT
2. J Clin Oncol. 22:785–794. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Citri A and Yarden Y: EGF-ERBB signalling:
towards the systems level. Nat Rev Mol Cell Biol. 7:505–516. 2006.
View Article : Google Scholar
|
|
17
|
Kalyankrishna S and Grandis JR: Epidermal
growth factor receptor biology in head and neck cancer. J Clin
Oncol. 24:2666–2672. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saba NF, Shin DM and Khuri FR: Targeting
angiogenesis in head and neck cancer. Curr Cancer Drug Targets.
7:643–649. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wheeler DL, Huang S, Kruser TJ,
Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT and
Harari PM: Mechanisms of acquired resistance to cetuximab: role of
HER (ErbB) family members. Oncogene. 27:3944–3956. 2008. View Article : Google Scholar
|
|
21
|
Quintana E, Shackleton M, Sabel MS, Fullen
DR, Johnson TM and Morrison SJ: Efficient tumour formation by
single human melanoma cells. Nature. 456:593–598. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Civenni G, Walter A, Kobert N,
Mihic-Probst D, Zipser M, Belloni B, Seifert B, Moch H, Dummer R,
van den Broek M and Sommer L: Human CD271-positive melanoma stem
cells associated with metastasis establish tumor heterogeneity and
long-term growth. Cancer Res. 71:3098–3109. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Prince ME, Sivanandan R, Kaczorowski A,
Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF and Ailles
LE: Identification of a subpopulation of cells with cancer stem
cell properties in head and neck squamous cell carcinoma. Proc Natl
Acad Sci USA. 104:973–978. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Krishnamurthy S, Dong Z, Vodopyanov D, et
al: Endothelial cell-initiated signaling promotes the survival and
self-renewal of cancer stem cells. Cancer Res. 70:9969–9978. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Whiteside TL: Immunobiology and
immunotherapy of head and neck cancer. Curr Oncol Rep. 3:46–55.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Almand B, Resser JR, Lindman B, Nadaf S,
Clark JI, Kwon ED, Carbone DP and Gabrilovich DI: Clinical
significance of defective dendritic cell differentiation in cancer.
Clin Cancer Res. 6:1755–1766. 2000.PubMed/NCBI
|
|
27
|
Duray A, Demoulin S, Hubert P, Delvenne P
and Saussez S: Immune suppression in head and neck cancers: a
review. Clin Dev Immunol. 2010:7016572010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Saito T, Kuss I, Dworacki G, Gooding W,
Johnson JT and Whiteside TL: Spontaneous ex vivo apoptosis of
peripheral blood mononuclear cells in patients with head and neck
cancer. Clin Cancer Res. 5:1263–1273. 1999.PubMed/NCBI
|
|
29
|
Zamarron BF and Chen W: Dual roles of
immune cells and their factors in cancer development and
progression. Int J Biol Sci. 7:651–658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kuss I, Donnenberg AD, Gooding W and
Whiteside TL: Effector
CD8+CD45RO−CD27−T cells have
signalling defects in patients with squamous cell carcinoma of the
head and neck. Br J Cancer. 88:223–230. 2003.
|
|
31
|
Kuss I, Hathaway B, Ferris RL, Gooding W
and Whiteside TL: Decreased absolute counts of T lymphocyte subsets
and their relation to disease in squamous cell carcinoma of the
head and neck. Clin Cancer Res. 10:3755–3762. 2004. View Article : Google Scholar
|
|
32
|
Campoli M, Chang CC and Ferrone S: HLA
class I antigen loss, tumor immune escape and immune selection.
Vaccine. 20(Suppl 4): A40–A45. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vora AR, Rodgers S, Parker AJ, Start R,
Rees RC and Murray AK: An immunohistochemical study of altered
immunomodulatory molecule expression in head and neck squamous cell
carcinoma. Br J Cancer. 76:836–844. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kulkarni DP, Wadia PP, Pradhan TN, Pathak
AK and Chiplunkar SV: Mechanisms involved in the down-regulation of
TCR zeta chain in tumor versus peripheral blood of oral cancer
patients. Int J Cancer. 124:1605–1613. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Valitutti S, Müller S, Salio M and
Lanzavecchia A: Degradation of T cell receptor (TCR)-CD3-zeta
complexes after antigenic stimulation. J Exp Med. 185:1859–1864.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sparano A, Lathers DM, Achille N,
Petruzzelli GJ and Young MR: Modulation of Th1 and Th2 cytokine
profiles and their association with advanced head and neck squamous
cell carcinoma. Otolaryngol Head Neck Surg. 131:573–576. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Whiteside TL: Anti-tumor vaccines in head
and neck cancer: targeting immune responses to the tumor. Curr
Cancer Drug Targets. 7:633–642. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jebreel A, Mistry D, Loke D, Dunn G, Hough
V, Oliver K, Stafford N and Greenman J: Investigation of
interleukin 10, 12 and 18 levels in patients with head and neck
cancer. J Laryngol Otol. 121:246–252. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shevach EM: Regulatory/suppressor T cells
in health and disease. Arthritis Rheum. 50:2721–2724. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cesana GC, DeRaffele G, Cohen S,
Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C,
Kim-Schulze S and Kaufman HL: Characterization of
CD4+CD25+ regulatory T cells in patients
treated with high-dose interleukin-2 for metastatic melanoma or
renal cell carcinoma. J Clin Oncol. 24:1169–1177. 2006.PubMed/NCBI
|
|
41
|
Mizukami Y, Kono K, Kawaguchi Y, Akaike H,
Kamimura K, Sugai H and Fujii H: Localisation pattern of
Foxp3+ regulatory T cells is associated with clinical
behaviour in gastric cancer. Br J Cancer. 98:148–153.
2008.PubMed/NCBI
|
|
42
|
Strauss L, Bergmann C and Whiteside TL:
Functional and phenotypic characteristics of
CD4+CD25highFoxp3+ Treg clones obtained from
peripheral blood of patients with cancer. Int J Cancer.
121:2473–2483. 2007.PubMed/NCBI
|
|
43
|
André F, Chaput N, Schartz NE, Flament C,
Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, et
al: Exosomes as potent cell-free peptide-based vaccine. I Dendritic
cell-derived exosomes transfer functional MHC class I/peptide
complexes to dendritic cells. J Immunol. 172:2126–2136.
2004.PubMed/NCBI
|
|
44
|
Mende I and Engleman EG: Breaking
tolerance to tumors with dendritic cell-based immunotherapy. Ann NY
Acad Sci. 1058:96–104. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Steinman RM: Dendritic cells:
understanding immunogenicity. Eur J Immunol. 37(Suppl 1): S53–S60.
2007. View Article : Google Scholar
|
|
46
|
Todryk S: A sense of tumour for the immune
system. Immunology. 107:1–4. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cools N, Ponsaerts P, Van Tendeloo VF and
Berneman ZN: Balancing between immunity and tolerance: an interplay
between dendritic cells, regulatory T cells, and effector T cells.
J Leukoc Biol. 82:1365–1374. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Almand B, Clark JI, Nikitina E, van Beynen
J, English NR, Knight SC, Carbone DP and Gabrilovich DI: Increased
production of immature myeloid cells in cancer patients: a
mechanism of immunosuppression in cancer. J Immunol. 166:678–689.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tas MP, Simons PJ, Balm FJ and Drexhage
HA: Depressed monocyte polarization and clustering of dendritic
cells in patients with head and neck cancer: in vitro restoration
of this immunosuppression by thymic hormones. Cancer Immunol
Immunother. 36:108–114. 1993. View Article : Google Scholar
|
|
50
|
Gabrilovich DI, Chen HL, Girgis KR, et al:
Production of vascular endothelial growth factor by human tumors
inhibits the functional maturation of dendritic cells. Nat Med.
2:1096–1103. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Allavena P, Piemonti L, Longoni D,
Bernasconi S, Stoppacciaro A, Ruco L and Mantovani A: IL-10
prevents the differentiation of monocytes to dendritic cells but
promotes their maturation to macrophages. Eur J Immunol.
28:359–369. 1998. View Article : Google Scholar
|
|
52
|
Péguet-Navarro J, Moulon C, Caux C,
Dalbiez-Gauthier C, Banchereau J and Schmitt D: Interleukin-10
inhibits the primary allogeneic T cell response to human epidermal
Langerhans cells. Eur J Immunol. 24:884–891. 1994.PubMed/NCBI
|
|
53
|
Steinbrink K, Wölfl M, Jonuleit H, Knop J
and Enk AH: Induction of tolerance by IL-10-treated dendritic
cells. J Immunol. 159:4772–4780. 1997.PubMed/NCBI
|
|
54
|
Cerwenka A and Lanier LL: Natural killer
cells, viruses and cancer. Nat Rev Immunol. 1:41–49. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yokoyama WM, Kim S and French AR: The
dynamic life of natural killer cells. Annu Rev Immunol. 22:405–429.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lee SC, Srivastava RM, López-Albaitero A,
Ferrone S and Ferris RL: Natural killer (NK): dendritic cell (DC)
cross talk induced by therapeutic monoclonal antibody triggers
tumor antigen-specific T cell immunity. Immunol Res. 50:248–254.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
González FM, Vargas JA, López-Cortijo C,
Castejón R, Gorriz C, Ramírez-Camacho R, Millán I and Durántez A:
Prognostic significance of natural killer cell activity in patients
with laryngeal carcinoma. Arch Otolaryngol Head Neck Surg.
124:852–856. 1998.
|
|
58
|
Thomas L: On immunosurveillance in human
cancer. Yale J Biol Med. 55:329–33. 1982.PubMed/NCBI
|
|
59
|
Schreiber RD, Old LJ and Smyth MJ: Cancer
immunoediting: integrating immunity’s roles in cancer suppression
and promotion. Science. 331:1565–1570. 2011.PubMed/NCBI
|
|
60
|
Dunn GP, Bruce AT, Ikeda H, Old LJ and
Schreiber RD: Cancer immunoediting: from immunosurveillance to
tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Vattemi E and Claudio PP: The feasibility
of gene therapy in the treatment of head and neck cancer. Head Neck
Oncol. 1:32009. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Morgan RA, Dudley ME, Wunderlich JR,
Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US,
Restifo NP, et al: Cancer regression in patients after transfer of
genetically engineered lymphocytes. Science. 314:126–129. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Abuzeid WM, Li D and O’Malley BW Jr: Gene
therapy for head and neck cancer. Adv Otorhinolaryngol. 70:141–151.
2011.PubMed/NCBI
|
|
64
|
De Costa AM and Young MR: Immunotherapy
for head and neck cancer: advances and deficiencies. Anticancer
Drugs. 22:674–681. 2011.PubMed/NCBI
|
|
65
|
Harrington KJ, Nutting CM and Pandha HS:
Gene therapy for head and neck cancer. Cancer Metastasis Rev.
24:147–164. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
O’Malley BW, Cope KA, Chen SH, Li D,
Schwarta MR and Woo SL: Combination gene therapy for oral cancer in
a murine model. Cancer Res. 56:1737–1741. 1996.PubMed/NCBI
|
|
67
|
Case SS, Price MA, Jordan CT, Yu XJ, Wang
L, Bauer G, Haas DL, Xu D, Stripecke R, Naldini L, et al: Stable
transduction of quiescent CD34(+)CD38(−) human hematopoietic cells
by HIV-1-based lentiviral vectors. Proc Natl Acad Sci USA.
96:2988–2993. 1999.
|
|
68
|
Chang LJ and Gay EE: The molecular
genetics of lentiviral vectors - current and future perspectives.
Curr Gene Ther. 1:237–251. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Roe T, Reynolds TC, Yu G and Brown PO:
Integration of murine leukemia virus DNA depends on mitosis. EMBO
J. 12:2099–2108. 1993.PubMed/NCBI
|
|
70
|
Schroers R, Sinha I, Segall H, et al:
Transduction of human PBMC-derived dendritic cells and macrophages
by an HIV-1-based lentiviral vector system. Mol Ther. 1:171–179.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Kung SK, An DS, Bonifacino A, Metzger ME,
Ringpis GE, Mao SH, Chen IS and Donahue RE: Induction of
transgene-specific immunological tolerance in myeloablated nonhuman
primates using lentivirally transduced CD34+ progenitor
cells. Mol Ther. 8:981–991. 2003. View Article : Google Scholar
|
|
72
|
Montini E, Cesana D, Schmidt M, Sanvito F,
Ponzoni M, Bartholomae C, Sergi Sergi L, Benedicenti F, Ambrosi A,
Di Serio C, et al: Hematopoietic stem cell gene transfer in a
tumor-prone mouse model uncovers low genotoxicity of lentiviral
vector integration. Nat Biotechnol. 24:687–696. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Mahmood S, Kanwar N, Tran J, Zhang ML and
Kung SK: SHP-1 phosphatase is a critical regulator in preventing
natural killer cell self-killing. PLoS One. 7:e442442012.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Tran J, Mahmood S, Carlyle JR and Kung SK:
Altering the specificity of NK:target cell interactions by genetic
manipulation of NK receptor expression on primary mouse NK cells.
Vaccine. 28:3767–3772. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Hoffmann TK: Systemic therapy strategies
for head-neck carcinomas: Current status. GMS Curr Top
Otorhinolaryngol Head Neck Surg. 11:Doc032012.(In German).
|
|
76
|
Steeg PS: Metastasis suppressors alter the
signal transduction of cancer cells. Nat Rev Cancer. 3:55–63. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
78
|
Folgueras AR, Pendás AM, Sánchez LM and
López-Otín C: Matrix metalloproteinases in cancer: from new
functions to improved inhibition strategies. Int J Dev Biol.
48:411–424. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Noel A, Maillard C, Rocks N, Jost M,
Chabottaux V, Sounni NE, Maquoi E, Cataldo D and Foidart JM:
Membrane associated proteases and their inhibitors in tumour
angiogenesis. J Clin Pathol. 57:577–584. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Overall CM and López-Otín C: Strategies
for MMP inhibition in cancer: innovations for the post-trial era.
Nat Rev Cancer. 2:657–672. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
81
|
Liotta LA, Tryggvason K, Garbisa S, Hart
I, Foltz CM and Shafie S: Metastatic potential correlates with
enzymatic degradation of basement membrane collagen. Nature.
284:67–68. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Sun Y, Liu M, Yang B, Li B and Lu J: Role
of siRNA silencing of MMP-2 gene on invasion and growth of
laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol.
265:1385–1391. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Xie SM, Fang WY, Liu Z, Wang SX, Li X, Liu
TF, Xie WB and Yao KT: Lentivirus-mediated RNAi silencing targeting
ABCC2 increasing the sensitivity of a human nasopharyngeal
carcinoma cell line against cisplatin. J Transl Med. 6:552008.
View Article : Google Scholar
|
|
84
|
Siddik ZH: Cisplatin: mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Dean M, Hamon Y and Chimini G: The human
ATP-binding cassette (ABC) transporter superfamily. J Lipid Res.
42:1007–1017. 2001.PubMed/NCBI
|
|
86
|
Taniguchi K, Wada M, Kohno K, Nakamura T,
Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S and Kuwano
M: A human canalicular multispecific organic anion transporter
(cMOAT) gene is overexpressed in cisplatin-resistant human cancer
cell lines with decreased drug accumulation. Cancer Res.
56:4124–4129. 1996.
|
|
87
|
Balkwill F: The significance of cancer
cell expression of the chemokine receptor CXCR4. Semin Cancer Biol.
14:171–179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kang H, Watkins G, Douglas-Jones A, Mansel
RE and Jiang WG: The elevated level of CXCR4 is correlated with
nodal metastasis of human breast cancer. Breast. 14:360–367. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Sokolowska-Wojdylo M, Wenzel J, Gaffal E,
Lenz J, Speuser P, Erdmann S, Abuzahra F, Bowman E, Roszkiewicz J,
Bieber T and Tüting T: Circulating clonal CLA(+) and CD4(+) T cells
in Sezary syndrome express the skin-homing chemokine receptors CCR4
and CCR10 as well as the lymph node-homing chemokine receptor CCR7.
Br J Dermatol. 152:258–264. 2005.
|
|
90
|
Hong JS, Pai HK, Hong KO, Kim MA, Kim JH,
Lee JI, Hong SP and Hong SD: CXCR-4 knockdown by small interfering
RNA inhibits cell proliferation and invasion of oral squamous cell
carcinoma cells. J Oral Pathol Med. 38:214–219. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Chen YC, Chen YW, Hsu HS, Tseng LM, Huang
PI, Lu KH, Chen DT, Tai LK, Yung MC, Chang SC, et al: Aldehyde
dehydrogenase 1 is a putative marker for cancer stem cells in head
and neck squamous cancer. Biochem Biophys Res Commun. 385:307–313.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Chen YC, Chang CJ, Hsu HS, Chen YW, Tai
LK, Tseng LM, Chiou GY, Chang SC, Kao SY, Chiou SH and Lo WL:
Inhibition of tumorigenicity and enhancement of
radiochemosensitivity in head and neck squamous cell cancer-derived
ALDH1-positive cells by knockdown of Bmi-1. Oral Oncol. 46:158–165.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Badoual C, Sandoval F, Pere H, Hans S, Gey
A, Merillon N, Van Ryswick C, Quintin-Colonna F, Bruneval P, Brasnu
D, et al: Better understanding tumor-host interaction in head and
neck cancer to improve the design and development of
immunotherapeutic strategies. Head Neck. 32:946–958. 2010.
|
|
94
|
Young MR: Protective mechanisms of head
and neck squamous cell carcinomas from immune assault. Head Neck.
28:462–470. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Hathaway B, Landsittel DP, Gooding W,
Whiteside TL, Grandis JR, Siegfried JM, Bigbee WL and Ferris RL:
Multiplexed analysis of serum cytokines as biomarkers in squamous
cell carcinoma of the head and neck patients. Laryngoscope.
115:522–527. 2005. View Article : Google Scholar
|
|
96
|
Reichert TE, Rabinowich H, Johnson JT and
Whiteside TL: Mechanisms responsible for signaling and functional
defects. J Immunother. 21:295–306. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Planelles V and Benichou S: Vpr and its
interactions with cellular proteins. Curr Top Microbiol Immunol.
339:177–200. 2009.PubMed/NCBI
|
|
98
|
Poon B, Jowett JB, Stewart SA, Armstrong
RW, Rishton GM and Chen IS: Human immunodeficiency virus type 1 vpr
gene induces phenotypic effects similar to those of the DNA
alkylating agent, nitrogen mustard. J Virol. 71:3961–3971.
1997.
|
|
99
|
Stewart SA, Poon B, Song JY and Chen IS:
Human immunodeficiency virus type 1 vpr induces apoptosis through
caspase activation. J Virol. 74:3105–3111. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Pang S, Kang MK, Kung S, et al: Anticancer
effect of a lentiviral vector capable of expressing HIV-1 Vpr. Clin
Cancer Res. 7:3567–3573. 2001.PubMed/NCBI
|
|
101
|
Dai B, Yang L, Yang H, Hu B, Baltimore D
and Wang P: HIV-1 Gag-specific immunity induced by a
lentivector-based vaccine directed to dendritic cells. Proc Natl
Acad Sci USA. 106:20382–20387. 2009. View Article : Google Scholar
|
|
102
|
Morizono K, Xie Y, Ringpis GE, Johnson M,
Nassanian H, Lee B, Wu L and Chen IS: Lentiviral vector retargeting
to P-glycoprotein on metastatic melanoma through intravenous
injection. Nat Med. 11:346–352. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
103
|
Morizono K, Xie Y, Helguera G, Daniels TR,
Lane TF, Penichet ML and Chen IS: A versatile targeting system with
lentiviral vectors bearing the biotin-adaptor peptide. J Gene Med.
11:655–663. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Morizono K, Pariente N, Xie Y and Chen IS:
Redirecting lentiviral vectors by insertion of integrin-tageting
peptides into envelope proteins. J Gene Med. 11:549–558. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Saenz DT, Loewen N, Peretz M, Whitwam T,
Barraza R, Howell KG, Holmes JM, Good M and Poeschla EM:
Unintegrated lentivirus DNA persistence and accessibility to
expression in nondividing cells: analysis with class I integrase
mutants. J Virol. 78:2906–2920. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Apolonia L, Waddington SN, Fernandes C,
Ward NJ, Bouma G, Blundell MP, Thrasher AJ, Collins MK and Philpott
NJ: Stable gene transfer to muscle using non-integrating lentiviral
vectors. Mol Ther. 15:1947–1954. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Negri DR, Michelini Z, Baroncelli S, Spada
M, Vendetti S, Buffa V, Bona R, Leone P, Klotman ME and Cara A:
Successful immunization with a single injection of non-integrating
lentiviral vector. Mol Ther. 15:1716–1723. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Rahim AA, Wong AM, Howe SJ, Buckley SM,
Acosta-Saltos AD, Elston KE, Ward NJ, Philpott NJ, Cooper JD,
Anderson PN, et al: Efficient gene delivery to the adult and fetal
CNS using pseudotyped non-integrating lentiviral vectors. Gene
Ther. 16:509–520. 2009. View Article : Google Scholar
|
